Key facts
- This page summarizes Michael H. Davidson's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jan 2025, 17:21.
Michael H. Davidson - 06 Jan 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- NAMS
- Reported as of
- 06 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2025, 17:21:22 UTC
- Prior SEC filing
- 06 Jan 2025
- Next SEC filing
- 28 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael H. Davidson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael H. Davidson filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 06 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAMS
transaction
Ordinary Shares
Award
- Transaction value
- Shares
- +123,529
- Change %
- Price
- Shares after
- 123,529
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NAMS
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +670,467
- Change %
- Price
- $0.000000
- Shares after
- 670,467
- Date
- 06 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 670,467
- Exercise price
- $25.85
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represenets restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
Footnote F2
Each RSU was granted on January 7, 2025 for no consideration.
Footnote F3
25% of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.